JAKARTA – The sales of PT Kalbe Farma Tbk (KLBF) proliferated IDR 1 trillion to IDR 7.01 trillion in Q1 2022 from IDR 6.01 trillion reported in the same period last year. The increased revenue is supported by massive growth detected in the distribution and logistic segment of IDR 500 billion.
In the Financial Statement of Q1 2022 published earlier today (28/4), Vidjongtius, President Director of Kalbe Farma, listed that the distribution and logistic segment generated revenue of IDR 2.59 trillion, followed by the nutrition segment of IDR 1.88 trillion, prescription drugs of IDR 1.52 trillion, and health prosucts of IDR 1 trillion. For reference, in Q1 2021, the distribution and logistic segment’s contribution reached IDR 2 trillion, followed by the nutrition segment of IDR 1.65 trillion, prescribed drugs of IDR 1.39 trillion, and health products of IDR 951.65 billion.
Demographically, domestic sales contributed IDR 6.63 trillion, mainly covered by the distribution and logistic segment as stated above, followed by nutrition, prescription drugs, and health products segments. However, export sales were dominated by prescribed drugs, followed by health products, nutrition, and distribution and logistic segments.
As sales went up, so did its profit, allowing KLBF’s profit to swell from IDR 723.91 billion to IDR 852.66 billion. It also resulted from increases in other income and interest income, as well as declined other operational expenses. (LK/ZH)